ClinicalTrials.gg
CompletedNCT00036088Updated Jul 19, 2006

Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

A Phase 4 interventional study of Olanzapine in Schizophrenia, sponsored by Eli Lilly and Company. Completed at 60 sites in 12 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2006-07-19.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
530
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 97 studies testing olanzapine in Schizophrenia — 2 open to participants now, 3 under way, 1 of them phase 3. Olanzapine · Schizophrenia.

Enrollment
15th of 94
530 · median 114
Started
2001
with 4 others
Phase 4
46 of 97
1 open now
Registered
6th of 97
by date
Lead sponsor
22 of 97
Eli Lilly and Company

Among the 97 studies testing olanzapine in Schizophrenia, this one is the 15th largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2001, is one of 46 in phase 4, and was the 6th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 97 studies testing olanzapine in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About olanzapine

Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies testing olanzapine in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. You must be between the ages of 18 and 75. If you have reached your 76th birthday, you will not be able to participate
  2. You must have been diagnosed with schizophrenia
  3. You must be able to visit the doctor's office as scheduled for the next 7 months

Exclusion criteria

Exclusion:

  1. You have a serious medical illness, such as heart, liver, or kidney disease (Note: If you are uncertain about a particular condition, discuss it with your doctor.)
  2. You are either pregnant or breastfeeding
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
530 participants

Interventions

06

Study locations

60 sites
  • El Centro, California, United States
  • Glendale, California, United States
  • Sherman Oaks, California, United States
  • Middleton, Connecticut, United States
  • Norwich, Connecticut, United States
  • Melbourne, Florida, United States
  • Miami, Florida, United States
  • Atlanta, Georgia, United States
  • Chicago, Illinois, United States
  • Hoffman Estates, Illinois, United States
  • Lafayette, Indiana, United States
  • Rockville, Maryland, United States
  • Newton, Massachusetts, United States
  • St Charles, Missouri, United States
  • New York, New York, United States
  • Olean, New York, United States
  • Staten Island, New York, United States
  • Cincinnati, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Austin, Texas, United States
  • El Paso, Texas, United States
  • Houston, Texas, United States
  • Terrell, Texas, United States
  • Richmond, Virginia, United States
  • La Plata, Buenos Aires, Argentina
  • Godoy Cruz, Mendoza, Argentina
  • Buenos Aires, Argentina
  • Ciudad De Buenos Air, Argentina
  • Graz, Austria
  • Innsbruck, Austria
  • Linz, Austria
  • Wein, Austria
  • Wels, Austria
  • Salvador, Bahia, Brazil
  • Aparecida De Goiania, Goias, Brazil
  • Pelotas, RS, Brazil
  • Rio De Janeiro, Brazil
  • Sau Paulo, Brazil
  • Essen, Germany
  • Hamburg, Germany
  • Tubingen, Germany
  • Dublin, Ireland
  • Mexico City, Mexico
  • Lima, Peru
  • Cidra, Puerto Rico
  • Ponce, Puerto Rico
  • Rio Piedras, Puerto Rico
  • San Juan, Puerto Rico
  • Sama De Langreo, Asturias, Spain
  • San Boi De Llobregat, Barcelona, Spain
  • Elizondo, Navarra, Spain
  • Pamplona, Navarra, Spain
  • Barcelona, Spain
  • Camberwell, London, United Kingdom
  • Kings Lynn, Norfolk, United Kingdom
  • Paisley, Scotland, United Kingdom
  • Guildford, Surrey, United Kingdom
  • London, United Kingdom
  • Caracas, Venezuela
07

References and documents

Publications

  • Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry. 2011 May 17;11:87. doi: 10.1186/1471-244X-11-87. PubMed 21586165 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2001 and a completion of Jul 2002. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2002
First posted
May 8, 2002
Start
Aug 2001
Completion
Jul 2002
Last update
Jul 19, 2006
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Jul 19, 2006, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00036088
First posted
May 8, 2002
Start date
Aug 2001
Completion
Jul 2002
Last update
Jul 19, 2006
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion